documents

Regulatory documents from Regulations.gov including rules, proposed rules, notices, and supporting materials.

Data license: Public Domain (U.S. Government data) · Data source: Federal Register API & Regulations.gov API

13 rows where docket_id = "FDA-2007-D-0369" and posted_year = 2017 sorted by posted_date descending

✎ View and edit SQL

This data as json, CSV (advanced)

Suggested facets: subtype, posted_date, posted_month, comment_start_date, comment_end_date, open_for_comment, posted_date (date), comment_end_date (date), last_modified (date)

document_type 2

posted_year 1

  • 2017 · 13 ✖

agency_id 1

id agency_id docket_id title document_type subtype posted_date ▲ posted_year posted_month comment_start_date comment_end_date last_modified fr_doc_num open_for_comment withdrawn object_id
FDA-2007-D-0369-0431 FDA None FDA-2007-D-0369 Product-Specific Guidance for Methylphenidate Hydrochloride; New Draft Guidance for Industry; Availability Notice Notice of Availability 2017-10-23T04:00:00Z 2017 10 2017-10-23T04:00:00Z 2017-12-23T04:59:59Z 2017-10-23T14:27:17Z 2017-22891 0 0 0900006482bf72d7
FDA-2007-D-0369-0430 FDA None FDA-2007-D-0369 Product-Specific Guidances for Salmeterol Xinafoate and Fluticasone Propionate; Draft Guidances for Industry; Availability Notice Notice of Availability 2017-10-20T04:00:00Z 2017 10 2017-10-20T04:00:00Z 2017-12-20T04:59:59Z 2017-10-20T13:54:10Z 2017-22735 0 0 0900006482be9217
FDA-2007-D-0369-0429 FDA None FDA-2007-D-0369 Product-Specific Guidances; Draft and Revised Draft Guidances for Industry; Availability Notice Notice of Availability 2017-10-20T04:00:00Z 2017 10 2017-10-20T04:00:00Z 2017-12-20T04:59:59Z 2017-12-20T02:03:13Z 2017-22736 0 0 0900006482be91d2
FDA-2007-D-0369-0428 FDA None FDA-2007-D-0369 Product-Specific Guidance for Tiotropium Bromide; Draft Guidance for Industry; Availability Notice Notice of Availability 2017-10-20T04:00:00Z 2017 10 2017-10-20T04:00:00Z 2017-12-20T04:59:59Z 2017-12-20T02:03:36Z 2017-22734 0 0 0900006482be9196
FDA-2007-D-0369-0423 FDA None FDA-2007-D-0369 Product-Specific Guidance for Digoxin; Draft Revised Guidance for Industry; Availability Notice Notice of Availability 2017-08-30T04:00:00Z 2017 8 2017-08-30T04:00:00Z 2017-10-31T03:59:59Z 2024-11-07T01:10:58Z 2017-18386 1 0 0900006482af3e42
FDA-2007-D-0369-0421 FDA None FDA-2007-D-0369 Product-Specific Guidances; Final Guidances for Industry; Availability Notice Notice of Availability 2017-08-07T04:00:00Z 2017 8 2017-08-07T04:00:00Z   2017-08-07T14:53:59Z 2017-16581 0 0 09000064829c5600
FDA-2007-D-0369-0418 FDA None FDA-2007-D-0369 Product-Specific Guidances; Draft and Revised Draft Guidances for Industry; Availability Notice Notice of Availability 2017-07-14T04:00:00Z 2017 7 2017-07-14T04:00:00Z 2017-09-13T03:59:59Z 2022-08-04T18:35:31Z 2017-14781 0 0 09000064829219a8
FDA-2007-D-0369-0412 FDA None FDA-2007-D-0369 Product-Specific Guidances; Draft and Revised Draft Guidances for Industry; Availability Notice Notice of Availability 2017-05-17T04:00:00Z 2017 5 2017-05-17T04:00:00Z 2017-07-18T03:59:59Z 2017-09-06T01:03:54Z 2017-09961 0 0 09000064825cf1ee
FDA-2007-D-0369-0409 FDA None FDA-2007-D-0369 Product-Specific Guidance for Naloxone Hydrochloride; New Draft Guidance for Industry; Availability Notice Notice of Availability 2017-04-24T04:00:00Z 2017 4 2017-04-24T04:00:00Z 2017-06-24T03:59:59Z 2017-06-17T13:02:02Z 2017-08199 0 0 090000648256cde8
FDA-2007-D-0369-0407 FDA None FDA-2007-D-0369 Draft Guidance on Rifaximin re Product-Specific Guidances for Rifaximin; Revised Draft Guidance for Industry; Availability Other Guidance 2017-03-16T04:00:00Z 2017 3 2017-03-16T04:00:00Z   2024-11-07T00:56:39Z   1 0 090000648250ca6d
FDA-2007-D-0369-0406 FDA None FDA-2007-D-0369 Product-Specific Guidances for Rifaximin; Revised Draft Guidance for Industry; Availability Notice Notice of Availability 2017-03-16T04:00:00Z 2017 3 2017-03-16T04:00:00Z 2017-05-16T03:59:59Z 2017-05-16T01:01:05Z 2017-05245 0 0 090000648250c619
FDA-2007-D-0369-0403 FDA None FDA-2007-D-0369 Bioequivalence Recommendations for Difluprednate; Revised Draft Guidance for Industry; Availability Notice Notice of Availability 2017-02-15T05:00:00Z 2017 2 2017-02-15T05:00:00Z 2017-04-18T03:59:59Z 2017-02-23T16:47:31Z 2017-02972 0 0 09000064824c2630
FDA-2007-D-0369-0402 FDA None FDA-2007-D-0369 Supplemental Comment from Mylan Other Supplemental Comment 2017-02-09T05:00:00Z 2017 2 2017-02-09T05:00:00Z   2017-02-09T17:38:45Z   0 0 09000064824b6f72

Advanced export

JSON shape: default, array, newline-delimited, object

CSV options: 

CREATE TABLE documents (
    id TEXT PRIMARY KEY,
    agency_id TEXT,
    docket_id TEXT REFERENCES dockets(id),
    title TEXT,
    document_type TEXT,
    subtype TEXT,
    posted_date TEXT,
    posted_year INTEGER,
    posted_month INTEGER,
    comment_start_date TEXT,
    comment_end_date TEXT,
    last_modified TEXT,
    fr_doc_num TEXT,
    open_for_comment INTEGER,
    withdrawn INTEGER,
    object_id TEXT
);
CREATE INDEX idx_docs_agency ON documents(agency_id);
CREATE INDEX idx_docs_docket ON documents(docket_id);
CREATE INDEX idx_docs_date ON documents(posted_date);
CREATE INDEX idx_docs_year ON documents(posted_year);
CREATE INDEX idx_docs_type ON documents(document_type);
CREATE INDEX idx_docs_frnum ON documents(fr_doc_num);
CREATE INDEX idx_docs_comment_end ON documents(comment_end_date) WHERE comment_end_date IS NOT NULL AND withdrawn = 0;